These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 3109461

  • 1. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.
    James CA, Mant TG, Rogers HJ.
    Br J Clin Pharmacol; 1987 May; 23(5):561-8. PubMed ID: 3109461
    [Abstract] [Full Text] [Related]

  • 2. Bioavailability of orally administered mesna.
    Burkert H, Lücker PW, Wetzelsberger N, Breuel HP.
    Arzneimittelforschung; 1984 May; 34(11):1597-600. PubMed ID: 6441581
    [Abstract] [Full Text] [Related]

  • 3. Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing.
    Shaw IC, Weeks MS.
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):933-5. PubMed ID: 3117563
    [Abstract] [Full Text] [Related]

  • 4. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
    Goren MP, Houle JM, Bush DA, Li JT, Newman CE, Brade WP.
    Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.
    el-Yazigi A, Ernst P, al-Rawithi S, Legayada E, Raines DA.
    J Clin Pharmacol; 1997 Jul; 37(7):618-24. PubMed ID: 9243355
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.
    Ormstad K, Orrenius S, Låstbom T, Uehara N, Pohl J, Stekar J, Brock N.
    Cancer Res; 1983 Jan; 43(1):333-8. PubMed ID: 6401168
    [Abstract] [Full Text] [Related]

  • 7. The fate of [14C]-mesna in the rat.
    Shaw IC, Graham MI, Jones MS.
    Arzneimittelforschung; 1986 Mar; 36(3):487-9. PubMed ID: 3085684
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The interactions of mesna and dimesna with the sulfate exchange in human red blood cells.
    Reuther H, Kohl M, Wildenauer DB.
    Arzneimittelforschung; 1986 Apr; 36(4):763-5. PubMed ID: 3087373
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
    Habs MR, Schmähl D.
    Cancer; 1983 Feb 15; 51(4):606-9. PubMed ID: 6401591
    [Abstract] [Full Text] [Related]

  • 12. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
    Brock N, Stekar J.
    Arzneimittelforschung; 1982 Feb 15; 32(5):486-7. PubMed ID: 6809014
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.
    Goren MP, Anthony LB, Hande KR, Johnson DH, Brade WP, Frazier MW, Bush DA, Li JT.
    J Clin Oncol; 1998 Feb 15; 16(2):616-21. PubMed ID: 9469350
    [Abstract] [Full Text] [Related]

  • 17. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V, Wagner T.
    Cancer Chemother Pharmacol; 1997 Feb 15; 39(5):431-9. PubMed ID: 9054957
    [Abstract] [Full Text] [Related]

  • 18. Liquid chromatographic analysis of mesna and dimesna in plasma and urine of patients treated with mesna.
    el-Yazigi A, Yusuf A, al-Rawithi S.
    Ther Drug Monit; 1995 Apr 15; 17(2):153-8. PubMed ID: 7624904
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration].
    Roth B, Cerny T, Brunner KW, Küpfer A.
    Schweiz Med Wochenschr; 1989 Aug 26; 119(34):1153-8. PubMed ID: 2510294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.